Phase I/II Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab (MEDI4736) for High Risk Non-Muscle Invasive Bladder Cancer
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Acronyms Rideau
- 27 Oct 2023 Planned End Date changed from 1 Sep 2026 to 1 May 2022.
- 27 Oct 2023 Planned primary completion date changed from 1 Sep 2026 to 1 May 2022.
- 17 Nov 2021 New trial record